Cingulate (CING) Operating Leases (2021 - 2026)

Cingulate's (CING) quarterly Operating Leases came in at $1.1 million in Q4 2025, down 5.39% on a QoQ basis from $1.2 million in Q3 2025.

Cingulate (CING) Operating Leases (2021 - 2026) Analysis & Trends

Cingulate (CING) has 5 years of Operating Leases data on file, last reported at $1.1 million in Q4 2025.

Quarterly Operating Leases changed N/A year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (changed N/A YoY) and the FY2025 annual result came in at $1.1 million, changed N/A from the prior year.
Operating Leases eased to $1.1 million in Q4 2025, from $1.2 million in the prior quarter.
In the past five years, Operating Leases ranged from a high of $1.2 million in Q3 2025 to a low of $33145.0 in Q1 2024.
A 5-year average of $557191.3 and a median of $533649.5 in 2022 frame the typical range for Operating Leases.
Annual changes were most pronounced in 2022 — Operating Leases plunged 41.01% — and 2024, when it plunged 91.83%.
Tracing CING's Operating Leases over 5 years: stood at $828503.0 in 2021, then sank by 41.01% to $488748.0 in 2022, then sank by 73.27% to $130663.0 in 2023, then slumped by 74.63% to $33145.0 in 2024, then jumped by 3219.42% to $1.1 million in 2025.
The last three Operating Leases figures came in at $1.1 million (Q4 2025), $1.2 million (Q3 2025), and $33145.0 (Q1 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cingulate	72.85 Mn	72.85 Mn	-

Download Data